Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors
    Meeting Abstract

    Dooley, A.; Han, K.; Zhi, W. I.; Piulson, L.; Seluzicki, C.; Bao, T.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study
    Meeting Abstract

    Dejan, J.; Rugo, H. S.; Chia, S. K. L.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Ciruelos, E. M.; Neven, P.; Park, Y. H.; Arce, C. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic
    Meeting Abstract

    Dang, C. T.; Tolaney, S. M.; Riaz, F.; Tan, A. R.; Tkaczuk, K. H. R.; Yu, A. F.; Liu, J.; Fung, A. M.; Yang, A.; Day, B. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
    Meeting Abstract

    Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC)
    Meeting Abstract

    Bedard, P. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Im, S. A.; Sohn, J.; Tseng, L. M.; Anders, C. K.; Schmid, P.; Boston, S.; Darilay, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
    Meeting Abstract

    Aftimos, P. G.; Oliveira, M.; Punie, K.; Boni, V.; Hamilton, E. P.; Gucalp, A.; Shah, P. D.; de Miguel, M. J.; Sharma, P.; Bauman, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: Findings from the SUMMIT basket trial
    Meeting Abstract

    Goldman, J.; Bueno, A. M.; Dooms, C.; Jhaveri, K.; de Miguel, M. J.; Piha-Paul, S. A.; Unni, N.; Mahipal, A.; Suga, J. M.; Naltet, C.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Matching adjusted indirect comparison of PFS & OS comparing ribociclib + letrozole vs palbociclib + letrozole as first-line treatment of HR+/HER2− ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2
    Meeting Abstract

    Jhaveri, K.; O'Shaughnessy, J.; Fasching, P.; Cardoso, F.; Tolaney, S.; Hamilton, E.; Sharma, V. K.; Biswas, C.; Haftchenary, S.; Pathak, P.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save